{"protocolSection":{"identificationModule":{"nctId":"NCT00420316","orgStudyIdInfo":{"id":"109810"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.","officialTitle":"To Assess Long-term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in the Primary Vaccination Study (102247)."},"statusModule":{"statusVerifiedDate":"2018-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-02-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2007-08-08","type":"ACTUAL"},"completionDateStruct":{"date":"2007-08-08","type":"ACTUAL"},"studyFirstSubmitDate":"2007-01-10","studyFirstSubmitQcDate":"2007-01-10","studyFirstPostDateStruct":{"date":"2007-01-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-01-05","resultsFirstSubmitQcDate":"2017-01-05","resultsFirstPostDateStruct":{"date":"2017-02-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-07-23","lastUpdatePostDateStruct":{"date":"2018-08-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247). The Rotarix vaccine was administered in the primary vaccination study. There was no vaccine/intervention in this long-term efficacy study."},"conditionsModule":{"conditions":["Infections, Rotavirus"],"keywords":["Intussusception","Gastroenteritis","Finland"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1613,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rotarix Group","type":"EXPERIMENTAL","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.","interventionNames":["Biological: Rotarix (primary vaccination study)"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.","interventionNames":["Biological: Placebo (primary vaccination study)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rotarix (primary vaccination study)","description":"GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.","armGroupLabels":["Rotarix Group"]},{"type":"BIOLOGICAL","name":"Placebo (primary vaccination study)","description":"Two liquid oral doses of placebo","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE)","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"}],"secondaryOutcomes":[{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE)","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE) With G1 Serotype","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes. Only GE episodes in which wild-type RV strain of G1 serotype was identified in a stool specimen, were included in the efficacy analysis.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE) With G1 Serotype","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain of serotype G1 and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE) With Non-G1 Serotype","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain of non-G1 serotype was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE) With Non-G1 Serotype","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain of non-G1 serotype and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects With Severe Gastroenteritis (GE)","description":"Severe GE was defined as a GE episode requiring hospitalization and/or re-hydration therapy in a medical facility.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"An SAE was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)"},{"measure":"Number of Subjects Reporting Intussusception (IS)","description":"Intussusception is defined as the telescoping of the intestine.","timeFrame":"During the period starting from the end of the second follow-up up to the start of the study (up to 6 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female who has completed the second year efficacy follow-up of the primary vaccination study in Finland.\n* Written informed consent obtained from the parent or guardian of the subject.","healthyVolunteers":true,"sex":"ALL","minimumAge":"32 Months","maximumAge":"3 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Espoo","zip":"02100","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"GSK Investigational Site","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"GSK Investigational Site","city":"Helsinki","zip":"00930","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"GSK Investigational Site","city":"Jarvenpaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"GSK Investigational Site","city":"Kotka","zip":"48600","country":"Finland","geoPoint":{"lat":60.4664,"lon":26.94582}},{"facility":"GSK Investigational Site","city":"Kuopio","zip":"70100","country":"Finland","geoPoint":{"lat":62.89238,"lon":27.67703}},{"facility":"GSK Investigational Site","city":"Lahti","zip":"15140","country":"Finland","geoPoint":{"lat":60.98267,"lon":25.66151}},{"facility":"GSK Investigational Site","city":"Oulu","zip":"90100","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"GSK Investigational Site","city":"Pori","zip":"28120","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"GSK Investigational Site","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"GSK Investigational Site","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"GSK Investigational Site","city":"Tampere","zip":"33520","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"GSK Investigational Site","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"GSK Investigational Site","city":"Vantaa","zip":"01300","country":"Finland","geoPoint":{"lat":60.29414,"lon":25.04099}},{"facility":"GSK Investigational Site","city":"Vantaa","zip":"01600","country":"Finland","geoPoint":{"lat":60.29414,"lon":25.04099}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"109810","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Annotated Case Report Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109810","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.","groups":[{"id":"FG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"FG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1082"},{"groupId":"FG001","numSubjects":"531"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1070"},{"groupId":"FG001","numSubjects":"522"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"8"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"BG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1082"},{"groupId":"BG001","value":"531"},{"groupId":"BG002","value":"1613"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.2","spread":"1.12"},{"groupId":"BG001","value":"31.3","spread":"1.19"},{"groupId":"BG002","value":"31.23","spread":"1.14"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"510"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"776"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"572"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"837"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE)","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to any rotavirus gastroenteritis (RV GE) caused by the circulating wild-type rotavirus strain. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.691","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"34.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-348.7","ciUpperLimit":"88.9"}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE)","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to severe rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain was assessed. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who have received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.551","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"50.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3769.6","ciUpperLimit":"99.4"}]},{"type":"SECONDARY","title":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE) With G1 Serotype","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes. Only GE episodes in which wild-type RV strain of G1 serotype was identified in a stool specimen, were included in the efficacy analysis.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE) With G1 Serotype","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain of serotype G1 and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to severe rotavirus gastroenteritis (RVGE) caused by the wild-type rotavirus strain of serotype G1. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.33","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1822.5","ciUpperLimit":"100"}]},{"type":"SECONDARY","title":"Number of Subjects With Any Rotavirus Gastroenteritis (RVGE) With Non-G1 Serotype","description":"Occurence of any rotavirus gastroenteritis (RVGE) caused by the circulating wild-type rotavirus strain of non-G1 serotype was assessed in terms of number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to any rotavirus gastroenteritis (RVGE) caused by the wild-type rotavirus strain of non-G1 serotype. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"-97.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9610.8","ciUpperLimit":"80.5"}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis (RVGE) With Non-G1 Serotype","description":"Number of rotavirus gastroenteritis (RVGE) episodes caused by the wild-type rotavirus strain of non-G1 serotype and reported during the efficacy period, were presented by severity, using the Vesikari scale. The assessment of intensity of GE episodes was done using the 20-point Vesikari scale, according to which episodes with scores greater than or equal to (≥) 11 were labeled as severe.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to severe rotavirus gastroenteritis (RVGE) caused by the wild-type rotavirus strain of non-G1 serotype was assessed. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0","ciUpperLimit":"98.7"}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Gastroenteritis (GE)","description":"Severe GE was defined as a GE episode requiring hospitalization and/or re-hydration therapy in a medical facility.","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for efficacy, which included all subjects from the ATP efficacy cohort of the primary study (102247) who entered into the efficacy surveillance period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1065"},{"groupId":"OG001","value":"525"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy with respect to severe gastroenteritis (GE) was assessed. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.817","statisticalMethod":"Fisher Exact","paramType":"Percent reduction","paramValue":"-23.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-287.7","ciUpperLimit":"54.8"}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"An SAE was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.","populationDescription":"The analysis was performed on the Total Cohort, which included all subjects who participated in this follow up study with at least one vaccine administration documented in the primary study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the study period for the long-term follow-up (i.e. 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1082"},{"groupId":"OG001","value":"531"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Intussusception (IS)","description":"Intussusception is defined as the telescoping of the intestine.","populationDescription":"The analysis was performed on the Total Cohort, which included all subjects who participated in this follow up study with at least one vaccine administration documented in the primary study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the period starting from the end of the second follow-up up to the start of the study (up to 6 months)","groups":[{"id":"OG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."},{"id":"OG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1082"},{"groupId":"OG001","value":"531"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious adverse events (SAEs): during the study period for the long-term follow-up (i.e. 6 months)","eventGroups":[{"id":"EG000","title":"Rotarix Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.","seriousNumAffected":4,"seriousNumAtRisk":1082,"otherNumAffected":0,"otherNumAtRisk":1082},{"id":"EG001","title":"Placebo Group","description":"Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.","seriousNumAffected":7,"seriousNumAtRisk":531,"otherNumAffected":0,"otherNumAtRisk":531}],"seriousEvents":[{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1082},{"groupId":"EG001","numAffected":1,"numAtRisk":531}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1082},{"groupId":"EG001","numAffected":1,"numAtRisk":531}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1082},{"groupId":"EG001","numAffected":1,"numAtRisk":531}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1082},{"groupId":"EG001","numAffected":2,"numAtRisk":531}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1082},{"groupId":"EG001","numAffected":0,"numAtRisk":531}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1082},{"groupId":"EG001","numAffected":1,"numAtRisk":531}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1082},{"groupId":"EG001","numAffected":0,"numAtRisk":531}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1082},{"groupId":"EG001","numAffected":1,"numAtRisk":531}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D012400","term":"Rotavirus Infections"},{"id":"D007443","term":"Intussusception"},{"id":"D005759","term":"Gastroenteritis"}],"ancestors":[{"id":"D012088","term":"Reoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D007415","term":"Intestinal Obstruction"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C492457","term":"RIX4414 vaccine"}]}},"hasResults":true}